EDELWEISS Phase 2b clinical trial results of linzagolix (OBE2109) for the treatment of endometriosis related pain (Replay)
18 Jun 2018 at 8:00 a.m. ET
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
For investor relations, please contact: